SequelSEC

Arcturus Therapeutics Holdings Inc. ARCT

Pharmaceutical Preparations · CIK 0001768224 · Fiscal year ends 1231

Revenue
$29.37M
Fiscal year ended 2026-06-30
Operating income
-$102.30M
Fiscal year ended 2026-06-30
Free cash flow
-$72.82M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$323.50MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$11.38Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.3%20th
Revenue YoY growth-46.1%25th
Current ratio6.64x68th
Operating margin-93.0%60th
Net margin-80.2%56th
SBC / revenue31.0%55th
R&D / revenue136.8%47th
FCF margin-90.8%49th

Arcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $29.37M and net income of -$93.28M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Arcturus Therapeutics Holdings Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Arcturus Therapeutics Holdings Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$29.37M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$102.30M
Net income-$93.28M
Research & development$86.78M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$44.88M
Selling & marketingUnavailable

Balance

Arcturus Therapeutics Holdings Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$191.48M
Total assets$224.31M
Current assets$197.16M
Total liabilities$52.50M
Current liabilities$33.54M
Total equity incl. NCI$171.81M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.81M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$4.41M

Cash flow

Arcturus Therapeutics Holdings Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$72.73M
Capital expenditures$93.00K
Investing cash flow-$41.00K
Financing cash flow$12.93M
Net change in cash-$59.84M
Stock-based compensation$21.10M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.74M

Derived

Arcturus Therapeutics Holdings Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$72.82M
Gross marginUnavailable
Operating margin-348.3%
FCF margin-248.0%
SBC / revenue71.9%
Current ratio5.88x
Revenue YoY growth-76.0%
Net margin-317.6%
R&D / revenue295.5%
CapEx / revenue0.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ARCT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.